Jafaru Abu

Dr. Jafaru Abu Consultant Gynecological Oncology Surgery


Years of Experience : 20

Nationality : United Kingdom

Languages Known : English

Book Appointment

Biography

Dr. Jafaru Abu is a Consultant Gynecological Oncology Surgeon who, before joining Burjeel Medical City, he occupied a senior position at Nottingham University Hospitals, UK, and in a career span of three decades, has put in almost 20 years of extensive work in the obstetrics and gynecology specialty, across a chain of leading hospitals in the UK. During this term of his service, from 2003 to 2006, Dr. Abu was a Subspecialty Fellow in Gynecological Oncology/Senior Registrar in Obstetrics and Gynecology, at University Hospitals of Leicester, United Kingdom. He was a visiting Fellow in Gynecological Oncology at Royal Brisbane Hospital and Royal Women’s Hospital, Queensland, Australia, and Royal Northshore Hospital, Sydney, Australia.

During the early part of Dr. Abu’s career, he worked as a Specialist Registrar and Senior House Officer in obstetrics and gynecology in the UK. As for Dr. Jafaru Abu’s educational background, he was a brilliant academic performer throughout his studies and qualified in the profession with excellent undergraduate and post-graduate medical qualifications. After gaining his first degree in medicine, MBBS, from the University of Benin Medical School, Nigeria, Dr. Abu moved to the United Kingdom, where he undertook all his postgraduate training and qualified as a Member (and later a Fellow) of the Royal College of Obstetricians and Gynecologists, UK, (MRCOG, FRCOG) and gained the BSCCP Accreditation from the British Society for Colposcopy and Cervical Pathology. Dr. Abu also studied and gained a Master’s degree in clinical sciences from the University of Leicester, United Kingdom. Dr. Abu earned two certificates during his specialist training years: the certificate of completion of specialist training in obstetrics and gynecology specialty from the Royal College of Obstetricians and Gynecologists, UK, and the certificate of completion of sub-specialty training in gynecological oncology from the Postgraduate Medical Education and Training Board (PMETB) and the Royal College of Obstetricians and Gynecologists, UK. Dr. Abu was also a visiting Fellow at the Centre for Gynecological Cancers and Minimally Invasive Surgery at the Royal Brisbane Hospital and Royal Women’s Hospital in Queensland, Australia, in 2005 and the Royal Northshore Hospital in Sydney, Australia, in 2006. He was appointed as a Consultant Gynecological Oncology Surgeon at Nottingham University Hospitals in 2006, one of the UK’s biggest teaching hospitals. He led a significant transformation in the surgical management of gynecological cancers by pioneering the introduction of several surgical procedures. He was instrumental in introducing minimally invasive techniques (keyhole operations) in the direction of cancers of the womb, cervix (neck of the womb), and initial stages of ovarian cancer. Dr. Abu is well known for his exceptional ability to perform complex key-hole procedures both laparoscopically and with the DaVinci robot. He was one of the first gynecologists in the UK to do single-incision laparoscopic surgery (SILS), a “scarless” procedure. Dr. Abu is also well known for performing extensive surgery for advanced stages of ovarian cancer and led the Department of Gynecological Oncology at Nottingham University Hospital, UK, to become an Accredited Advanced Ovarian Cancer Cytoreductive Surgical Centre by the European Society of Gynecological Oncologists (ESGO). He was the Head of Gynecological Oncology at Nottingham University Hospitals, UK, until he joined Burjeel Holdings.

Committed to training other consultants, he established the annual Nottingham advanced laparoscopic training course for gynecology consultants across the United Kingdom in 2008, where he trained and mentored other consultant colleagues and Senior Trainees to acquire the skills needed for safe advanced laparoscopic surgery in women. The masterclass course has become extremely popular across Europe. He also teaches advanced laparoscopic surgical skills as a member of an international faculty of experts in the IRCAD minimally invasive surgical training center in Strasbourg, France.

A star performer throughout his career, Dr. Jafaru Abu has received several awards for his outstanding work. He is a recipient of the RCOG Ethicon Travel Award in 2005; the Hospital Doctor Merit Award for the one-stop Menstrual Clinic at University Hospitals of Leicester, UK; the first position award from The Royal Society of Medicine, Registrars’ Prize Meeting in Obstetrics and Gynecology; and the first prize for joint RCOG and the Trinidad Society of Obstetrics and Gynecology Meeting. In 1997, Dr. Abu also secured the second prize from the Oxfordshire Regional Health Authority Forum in Obstetrics and Gynecology at the OXFOG event. He was named to the Who’s Who in Medicine and Healthcare list in 2009 was also a big step in his career. His areas of expertise include,

  • All diagnosed or suspected gynecological cancers
  • Ovarian masses
  • Postmenopausal bleeding
  • Abnormal uterine bleeding
  • Abnormal PAP smears
  • Suspicious vulvar lesions
  • Suspicious cervical lesions
  • Cervical abnormalities
  • Cervical cancers
  • Uterine or womb cancers
  • Ovarian cancer
  • Vaginal cancers
  • Vulvar cancers
  • Post coital bleeding
  • Irregular menstrual bleeding
  • Uterine fibroids
  • Keyhole hysterectomy (laparoscopic or robot assisted)
  • Abdominal hysterectomy
  • Cytoreductive surgery (ultraradical surgery) for advanced stages of ovarian cancer
  • Pelvic and para-aortic lymphadenectomy (open/laparoscopic/robotic)
  • Radical hysterectomy (open/laparoscopic/robotic)
  • Pelvic exenterate surgery for locally recurrent gynecological cancers
  • Colposcopy
  • Hysteroscopy
  • Myomectomy (open/laparoscopic/robotic)
  • Vaginectomy (open/laparoscopic/robotic)
  • Fertility preservation surgery for cervical cancer (trachelectomy – simple or radical)
  • Laparoscopic cervical cerclage
  • Ovarian transposition procedures (laparoscopic or robotic)
  • Sentinel lymph nodes for cervical and endometrial cancers (laparoscopic or robotic)
  • Sentinel lymph nodes for vulvar cancer
  • Vulvectomy (radical or simple)
  • Groin nodes dissection

 

Awards & Achievements

  • Recipient of the RCOG Ethicon Travel Award in 2005
  • The Hospital Doctor Merit Award for the One-Stop Menstrual Clinic at University Hospitals of Leicester, UK
  • 1st Position Award from the Royal Society of Medicine, Registrars’ Prize Meeting in Obstetrics and Gynecology
  • 1st Prize for Joint RCOG and the Trinidad Society of Obstetrics and Gynecology Meeting
  • 2nd Prize from the Oxfordshire Regional Health Authority Forum in Obstetrics and Gynecology at the OXFOG Event
  • Named the Who’s Who in Medicine and Healthcare List in 2009

Research & Publications

  • Lipidomic Biomarkers in Polycystic Ovary Syndrome and Endometrial Cancer. International Journal of Molecular Sciences. 2020
  • An Unusual case of abdominal pain and weight loss – Clinical Vignette. Rheumatology. 2020
  • Sterol regulatory element binding protein-1 (SREBP1) gene expression is similarly increased in polycystic ovary syndrome and endometrial cancer. Acta Obstetrica Et Gynecologica Scandinavica. 2017
  • Up-regulation of genes involved in the insulin signaling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer. Mol Cell Endocrinol 2016
  • Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecol Oncol. 2014
  • Reviewing the molecular mechanisms which increase endometrial cancer (EC) risk in women with polycystic ovarian syndrome (PCOS): Time for paradigm shift? Gynecologic Oncology 2013
  • Clinical outcomes of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: Institutional experience and review of literature. The Am J Surg Path. 2012
  • Pelvic Actinomycosis, with secondary liver abscess; an unusual presentation. - European J Obstet Gynecol & Reprod Biol. 2012 The wellbeing of women following total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer. Gynaecol Surg. 2012
  • Do Surgical Techniques Used in Groin Lymphadenectomy for Vulval Cancer Affect Morbidity Rates? Intl J Gyn Cancers2011
  • Expression of RAR beta2 gene by real-time RT-PCR: Differential expression in normal subjects compared to cervical cancer patients normalized against GAPDH as a housekeeping gene. Eur J Obstet Gynecol & Reprod Biol. 2008
  • Adenosarcoma of an endometrial polyp in a 27-yr old nulligravid. Is conservative management appropriate? J Reprod Med. 2007
  • Serum levels of retinol in patients with cervical cancer compared to normals. Measurement by HPLC. Journal of Clinical Oncology 2006
  • Should women with postcoital bleeding be referred for colposcopy? (The risk of significant pathology in patients presenting with postcoital bleeding at a major gynecological department in a UK Teaching Hospital). Journal of Obstet & Gynaecol 2006
  • Endometrial cancer in a 35-yr old woman with levonorgestrel intrauterine contraceptive device in-situ. Int J Gyn Cancers. 2006
  • Mesovarian hemangioma associated with massive ascites and elevated CA125. Int J Gyn Cancers. 2006 Aggressive angiomyxoma of the perineum. Int J Gyn Cancers. 2005
  • Retinoic acid and retinoid receptors: potential chemo preventive and/or therapeutic role in cancer of the uterine cervix. Lancet Oncology 2005
  • Endocervical Curettage at the time of colposcopy assessment of the uterine cervix. The Obstetrician and Gynecologist. 2005
  • The Current Management of Invasive Cervical Cancer. The Obstetrician and Gynecologist. 2004
  • Imaging techniques in the diagnosis of ovarian cancer. ObGyn Women’s Health. 2004
  • Malignant progression through borderline changes in recurrent Mullerian papilloma of the vagina. Journal of Histopathology. 2003
  • Ectopic pregnancy in the levonorgestrel releasing intrauterine system user. J Obst Gyn. 2002
  • Quantitative and Qualitative assessment of women’s experience of a one-stop menstrual clinic. BJOG 2001
  • Leukotrienes in gynecology: the hypothetical value of anti-leukotrienes in dysmenorrhea and endometriosis. Human Reproduction Update (European Society of Human Reproduction and Embryology)2000
  • The Brace suture technique for the control of massive postpartum hemorrhage: an alternative to hysterectomy. Five cases reported. British J of Obst Gyn. 1997
  • Gynecological Malignancies: Textbook of Pre-conceptual Medicine and Management. P399-410. Sapiens Publishing Ltd. 2012
  • Incongruous pathological and radiological response in a case of a mucin secreting adenocarcinoma of the cervix: 21st European Congress on Gynecological Oncology. 2019
  • Surgical outcome of cytoreductive surgery in metastatic ovarian cancer: IGCS, Kyoto, Japan. 2018
  • Morbidity associated with extensive cytoreductive surgery for advanced stages of ovarian cancer: IGCS, Kyoto, Japan. 2018
  • Outcomes of fertility preserving surgery with trachelectomy for early stage of cervical cancer at a major UK cancer centre: IGCS, Kyoto, Japan. 2018
  • Laparoscopic radical hysterectomy with vaginectomy for a primary malignant melanoma of uterine cervix with isolated lower vaginal metastasis. IVW, Prague. 2018
  • Outcome of advanced ovarian cancer, Nottingham Cancer Centre Experience. IGCS, Lisbon, Portugal. 2016
  • Total Laparoscopic Hysterectomy in morbidly obese women with endometrial cancer/hyperplasia: Nottingham University Hospital Experience. ESGO, Nice, France. 2015
  • A review on the Initial Management of Ovarian Cancer in Nottingham. BGCS, Newcastle, UK. 2015
  • Surgical and Quality of life outcomes in patients with stage 1a1 cervical carcinoma. IGCS, Melbourne, Australia. 2014
  • A review of post operative outcomes following extensive radical debulking surgery for advanced stage ovarian cancer. IGCS, Melbourne, Australia. 2014
  • A review of surgically managed endometrial cancer at Nottingham University Hospitals. BGCS, UK. 2014
  • The management of cervical cancer in pregnancy; a case report and literature review. BGCS, UK. 2014
  • Type 2 Endometrial Cancer. What is the optimal management? IGCS meeting, Liverpool, UK, 2013
  • Comparing the Urological Outcome of standard Type 3 Total Laparoscopic Radical Hysterectomy vs Type C1 (nerve-sparing) Total Laparoscopic Radical Hysterectomy. IGCS, Liverpool, UK. 2013
  • Single Institution initial experience outcome following Total Laparoscopic Radical Hysterectomy (TLRH) and Open Radical Hysterectomy for Early-Stage Cervical Cancer. IGCS Meeting in Vancouver, Canada. 2012
  • Total Laparoscopic Radical Hysterectomy vs Open Radical Hysterectomy. BGCS Meeting in London. 2012
  • An unusual method of extracting the uterus intact following a difficult total laparoscopic hysterectomy for endometrial cancer in an obese woman with large uterine fibroids. IJGS 2012

Membership

  • Royal College of Obstetricians and Gynecologists (RCOG)
  • British Society for Colposcopy and Cervical Pathology (BSCCP)
  • British Gynecological Cancer Society (BGCS)
  • Formerly a Member of the Subspecialty Training Council of the BGCS
  • International Gynecological Cancer Society (IGCS)
  • European Society of Gynecological Oncologists (ESGO)
  • European Society of Gynecological Endoscopists (ESGE)
  • British and Irish Association of Robotic Gynecologists (BIARGS)
  • British Medical Association (BMA)
  • Medical Staffing Research Committee, Nottingham University Hospital (MSRC)

Blogs